Skye Bioscience Inc.

Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company’s operational and clinical expertise. Read the full article here: https://bit.ly/3LbCm0q

"We are pleased to be included in the Russell indexes, a widely recognized benchmark for small-cap stocks, which is a testament to Skye’s recent accomplishments,” said Kaitlyn Arsenault, CPA, CFO. Read the full article here: https://bit.ly/4cmCjLr

Skye concentrates strategy and clinical development on Nimacimab metabolic program and discontinues SBI-100 Ophthalmic Emulsion program. Phase 2 study of Nimacimab in obesity expected to start in Q3 2024.

On Wednesday June 5th, Skye Bioscience's CSO Chris Twitty will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference 2024. You can listen to the webcast here: https://lnkd.in/g86ERASA

On Monday May 13th, Skye Bioscience's CEO and Chair Punit Dhillon will present an overview of the company at the Citizens JMP Securities Life Sciences Conference 2024. Listen live at 11:30 am ET or to the recording afterwards by registering here: https://lnkd.in/gDSZSds4

Skye is limitless and we are excited to announce we are growing our team 🚀 We are looking for a Senior Clinical Research Scientist to join our R&D team to help develop, plan and execute clinical biomarker studies. This person will be reporting to our Chief Scientific Officer, Chris Twitty, and be responsible for reviewing, analyzing and presenting clinical trial data from metabolic studies. This is an exciting time to join our fast growing team. Use the link below to apply! https://lnkd.in/gxg4T-ky

“Our mission at Skye is very simple. We’re absolutely interested in developing precision therapeutics and pharmaceuticals that help patients.” Skye Bioscience Inc. CEO Punit Dhillon reflects on the clinical-stage biotechnology company’s mission and how being #NasdaqListed helps them to deliver on that mission.

The $SKYE is limitless for Skye Bioscience Inc. as they celebrate their recent listing at the Nasdaq Opening Bell. 🛎️✨ $SKYE is a pharmaceuticals company developing proprietary molecules to treat diseases involving inflammatory, fibrotic and metabolic conditions. Congratulations! #NasdaqListed 👏

After uplisting to the Nasdaq Global Market last week, Skye Bioscience, Inc. will be ringing the Nasdaq bell this Thursday, April 18 at 6:30am PST/9:30am EST! Join us as we mark this exciting milestone in our journey. Stay tuned for the broadcasting link to watch live, coming tomorrow morning! Nasdaq Exchange #SkyeBioscience #NasdaqBellRing

Skye Bioscience has uplisted to the Nasdaq Global Market, a significant step mirroring its fundamental accomplishments, fundamental life science investors, and capital raised in in the last quarters. We now look forward to reporting Phase 2 glaucoma data in Q2 and starting the Phase 2 obesity study for our CB1 inhibitor in Q3. For additional details, read the full press release here: http://bit.ly/40nVSNO